Clinical ophthalmology (Auckland, N.Z.)最新文献

{"title":"Home Tonometry Diurnal Intraocular Pressure Patterns, Patient Adherence, and Measurement Reliability in a Prospective Clinical Cohort.","authors":"Scott W Perkins, Julia H Joo, Kevin C Allan, Shalini Sood, Matthew James Schulgit, George A Markakis, Ang Li","doi":"10.2147/OPTH.S545165","DOIUrl":"10.2147/OPTH.S545165","url":null,"abstract":"<p><strong>Purpose: </strong>Assess patient adherence, diurnal intraocular pressure patterns, and correlation with in-office tonometry of home intraocular pressure monitoring (IOP).</p><p><strong>Patients and methods: </strong>In this prospective cohort study, 75 patients with open-angle disease (150 eyes) were recruited and loaned the iCare HOME2 tonometer (ICH2) after in-person training and instructed to take 6 measurements per day for 10 ± 4 days. Statistical analysis of adherence, diurnal IOP patterns, and correlation with in-office tonometry was conducted.</p><p><strong>Results: </strong>Most patients had good adherence (65% of patients took ≥ 6 measurements per day, median 7.4 measurements/day). However, adherence was poor for a notable minority of patients (19% of patients took less than 2 measurements per day). Patients with low adherence reported difficulty obtaining measurements and desire for more training with the ICH2 device. ICH2 identified diurnal patterns of IOP fluctuation: IOP varied significantly over the 24-hour day (p < 0.0001), and early morning peak IOP at 3 AM decreased significantly throughout the day to minimum mean IOP at 10 PM (p < 0.0001). IOP variance was significantly greater outside of clinic hours (p < 0.0001) and 36% of patients had maximum IOP outside of clinic hours. In-office IOP measurements had significant positive correlation to the closest ICH2 measurement obtained by the patient in time for both Goldman applanation (r² = 0.35, p < 0.0001) and iCare IC100 (r² = 0.48, p < 0.0001).</p><p><strong>Conclusion: </strong>ICH2 is clinically useable and effective for detecting out-of-office IOP spikes, diurnal IOP patterns, and IOP variation.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"3547-3556"},"PeriodicalIF":0.0,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482958/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145208785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Keratometric Changes After Ab Interno Gel Stent Implantation, Glaucoma Drainage Devices and Trabeculectomy.","authors":"Kenan Bachour, Dominique Geoffrion, Guillaume A Mullie, Younes Agoumi, Georges M Durr","doi":"10.2147/OPTH.S536897","DOIUrl":"10.2147/OPTH.S536897","url":null,"abstract":"<p><strong>Purpose: </strong>To compare postoperative keratometric changes and surgically induced astigmatism (SIA) after Ab Interno Gel Stent Implantation (XEN), glaucoma drainage device (GDD), and trabeculectomy (TRAB). GDDs included Ahmed glaucoma valve (AGV) and Baerveldt glaucoma implant (BGI).</p><p><strong>Design: </strong>Prospective, interventional, longitudinal study.</p><p><strong>Participants and methods: </strong>Fifty-one eyes with glaucoma undergoing glaucoma filtering surgery were recruited between November 2020 and May 2023. The groups consisted of 19 XEN implants (37%), 21 GDDs (41%) (2 AGVs, 19 BGIs), and 11 trabeculectomies (22%). Primary outcomes were SIA at 12 months postoperatively, measured by Pentacam (Scheimpflug imaging) and OPD-scan (topography). The arithmetic mean of SIA (M-SIA) and the centroid of SIA (C-SIA) were determined using vector analysis. Secondary outcomes included BCVA, IOP, number of meds, and complications.</p><p><strong>Results: </strong>At 12 months, C-SIA measured by tomography was similar across all groups (0.3 ± 1.0 D for XENs and GDDs and 0.4 ± 1.0 D for TRAB). Topography measurements demonstrated a C-SIA of 0.2 ± 0.9 D for XENs, 0.1 ± 0.9 D for GDD, and 0.6 ± 1.7 D for TRAB. TRAB showed a trend towards a higher proportion of eyes with >1D of astigmatism (73%) compared to the XEN (27%) and GDD groups (48%, p = 0.159).</p><p><strong>Conclusion: </strong>SIA was similar across groups when measured by tomography, while topography measurements indicated a trend towards more SIA with TRAB. Mean cylinder values at 12 months were higher in the TRAB group.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"3535-3545"},"PeriodicalIF":0.0,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482951/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145208829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparisons of Early Changes of Vascular Structure After Treatment with Faricimab and Aflibercept in Eyes with Macular Neovascularization by OCT Angiography.","authors":"Shinichiro Chujo, Hisashi Matsubara, Yoko Mase, Yukiko Muramoto, Kumiko Kato, Mineo Kondo","doi":"10.2147/OPTH.S549586","DOIUrl":"10.2147/OPTH.S549586","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate whether Faricimab, which targets Ang-2, can reduce macular neovascularization (MNV) metrics on OCTA compared with Aflibercept in treatment-naïve nAMD.</p><p><strong>Methods: </strong>Among 34 eyes treated with Aflibercept, 12 eyes were included; among 31 eyes treated with Faricimab, 14 eyes were included. Vessel area (Va) and junction density (JD) were measured using AngioTool over a 3-month loading period.</p><p><strong>Results: </strong>In the Faricimab group, mean Va changed from 0.14 mm² at baseline to 0.15 mm² at 3 months; JD changed from 0.16 to 0.15/mm. In the Aflibercept group, Va decreased from 0.29 to 0.20 mm², and JD changed from 0.77 to 0.83/mm. Differences in Va and JD between groups were not statistically significant.</p><p><strong>Conclusion: </strong>There were no significant structural changes in MNV with either drug over the short term. These findings suggest that vascular effects of Faricimab may require longer observation to become evident.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"3527-3533"},"PeriodicalIF":0.0,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12476195/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145187776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Central Macular Thickness and Foveal Avascular Zone are Indicators of Early Diabetic Retinopathy.","authors":"Qingquan Wei, Wenying Wang, Qinghua Qiu","doi":"10.2147/OPTH.S544037","DOIUrl":"10.2147/OPTH.S544037","url":null,"abstract":"<p><strong>Purpose: </strong>Diabetic retinopathy (DR) is one of the most common complications in diabetic patients, and early diagnosis and intervention are crucial for slowing disease progression. This study aims to investigate the changes in central macular thickness (CMT) and foveal avascular zone (FAZ) area in healthy individuals, patients with no apparent diabetic retinopathy (NDR), and patients with non-proliferative diabetic retinopathy (NPDR), and to explore the potential risk factors for early DR.</p><p><strong>Methods: </strong>This cross-sectional study included 60 healthy individuals, 60 patients with no DR, and 60 patients with mild NPDR. All participants underwent comprehensive ophthalmic examinations. Central macular thickness (CMT) was measured using optical coherence tomography (OCT), and the FAZ area was measured using optical coherence tomography angiography (OCTA). The potential associations between CMT and FAZ area and systemic risk factors for early DR (including duration of diabetes, body mass index (BMI), glycated hemoglobin (HbA1c), lipid profile, and blood pressure) were analyzed.</p><p><strong>Results: </strong>Significant differences in CMT and FAZ area were observed in both the right and left eyes of the NPDR and NDR groups compared to the control group (p<0.05). The CMT and FAZ area also showed significant differences between the NPDR and NDR groups (p<0.05). Additionally, CMT was positively correlated with the duration of diabetes, BMI, total cholesterol (TC), triglyceride (TG), systolic blood pressure, and diastolic blood pressure (p<0.05). FAZ area was positively correlated with the duration of diabetes and BMI (p<0.05).</p><p><strong>Conclusion: </strong>The increase in CMT and the reduction in macular perfusion may be the earliest retinal structural changes in diabetic patients, and both changes are closely related to systemic factors. These findings provide important structural and metabolic indicators for the early identification and intervention of diabetic retinopathy.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"3505-3514"},"PeriodicalIF":0.0,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12474716/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145187638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Satisfaction and Visual and Refractive Outcomes Combining an Enhanced Monofocal and a Trifocal Intraocular Lens in Patients with Specific Visual Demands.","authors":"Fernando Mayordomo-Cerdá, Julio Ortega-Usobiaga, Rafael Bilbao-Calabuig, Fernando Llovet-Osuna, Juan Carlos Albelda-Vallés, Jaime Beltrán-Sanz, Julio Baviera-Sabater","doi":"10.2147/OPTH.S549693","DOIUrl":"10.2147/OPTH.S549693","url":null,"abstract":"<p><strong>Background: </strong>To assess subjective satisfaction and visual and refractive outcomes after combining an enhanced monofocal intraocular lens (IOL) and trifocal IOL in patients with specific visual demands.</p><p><strong>Methods: </strong>Patients underwent refractive lens exchange and received an enhanced monofocal lens (Tecnis Eyhance) in the dominant eye and a trifocal lens (FineVision) in the nondominant eye. At least 3 months after surgery, we evaluated subjective satisfaction, uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), uncorrected intermediate visual acuity (UIVA), uncorrected near visual acuity (UNVA), predictability, safety, and efficacy.</p><p><strong>Results: </strong>Sixty eyes from 30 patients met the inclusion criteria. At completion, postoperative binocular logMAR UNVA, UIVA, and UDVA were 0.10, 0.30, and 0.00, respectively. The change in visual acuity (before and after surgery, binocular) was statistically significant for UNVA and UDVA (p<0.01 and 0.004, respectively). Safety was better for the enhanced monofocal lens than for the trifocal lens (p=0.032), with no statistically significant differences in efficacy between the eyes. No eyes lost lines of CDVA. Predictability for ±0.5 D and ±1 D was better in eyes with FineVision and Eyhance, respectively, although the differences were not statistically significant. Patient satisfaction was high, enabling most patients to meet their special visual needs.</p><p><strong>Conclusion: </strong>Combining an enhanced monofocal IOL in the dominant eye with a trifocal IOL in the nondominant eye provides considerable satisfaction and spectacle independence and is safe and efficacious in patients with special visual requirements.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"3515-3526"},"PeriodicalIF":0.0,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12474665/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145187898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aganirsen as a Therapeutic Alternative for Modulating Corneal Neovascularization: A Real-World Case Series Study.","authors":"Salvador García-Delpech, Sara Fathi Nieto, Ana Hervás Ontiveros, Patricia Udaondo, Damian Garcia-Teillard","doi":"10.2147/OPTH.S545516","DOIUrl":"10.2147/OPTH.S545516","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the clinical benefits of aganirsen, an antisense oligonucleotide targeting insulin receptor substrate-1 (IRS-1), for reducing corneal neovascularization (CoNV) in patients scheduled for corneal transplantation.</p><p><strong>Patients and methods: </strong>Retrospective cohort study of patients who were treated with 1 drop of aganirsen (0.86 mg/mL) twice daily during 1 week preoperatively and at least 3 months after surgery. Changes in neovascularization were assessed qualitatively on slit-lamp examination.</p><p><strong>Results: </strong>The study population included 65 patients (males 61.5%), with a mean age of 60.3 years. Bilateral CoNV was observed in 1 patient only (1.5%). Main diagnoses included corneal dystrophy in 61.5% of patients, transplant rejection in 10.8%, herpes simplex keratitis and leucoma in 7.7% each, and mechanical trauma in 3.1%. A reduction of neovascularization was observed in all eyes (100%) after 3 months of treatment. Results were not influenced by demographic characteristics or diagnosis. Treatment with aganirsen made graft surgery unnecessary in 3 out of 65 patients (4.6%). Failure of corneal transplantation occurred in 5 out of 62 patients (8.1%). Diagnosis at presentation in these 5 patients were corneal dystrophy in 2, previous transplant rejection in 2, and herpetic keratouveitis in 1. Some patients presented minor conjunctival hyperemia, and 1 patient reported pruritus and discontinued the study at 2 months of treatment.</p><p><strong>Conclusion: </strong>This real-world study of the use of aganirsen months starting 1 week before graft surgery adds evidence of the clinical benefits of this agent in modulating neovascularization. Standardizing and extending the duration of treatment with aganirsen may further optimize the outcome of corneal transplantation.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"3497-3504"},"PeriodicalIF":0.0,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12474706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145187658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Anterion, MS-39, Pentacam, and Sirius in Corneal Assessment Prior to Refractive Surgery.","authors":"Mahmoud Anwar, Jens Bühren, Daniel Kook, Philipp Prahs, Wolfgang A Herrmann","doi":"10.2147/OPTH.S537050","DOIUrl":"10.2147/OPTH.S537050","url":null,"abstract":"<p><strong>Background: </strong>Accurate corneal evaluation is crucial for determining candidacy for refractive surgery.Devices combining diverse technologies, such as Scheimpflug imaging (Pentacam, Sirius), swept-source OCT (Anterion), and hybrid OCT/Placido systems (MS-39), offer distinct advantages and limitations in screening.</p><p><strong>Purpose: </strong>This study was conducted to compare corneal assessment with two Scheimpflug camera devices (Oculus Pentacam and CSO Sirius) and two spectral domain anterior segment optical coherence tomography devices (Heidelberg Engineering Anterion and CSO MS-39) in the preoperative screening of the cornea before refractive surgery.</p><p><strong>Methods: </strong>In this retrospective, consecutive case series, we enrolled 110 patients undergoing refractive surgery. Simulated keratometry (Sim-K), posterior keratometry (PK), central corneal thickness (CCT), keratometric astigmatism magnitude (KAM), Corneal diameter, Anterior chamber depth (ACD), and total corneal power (TCP) were compared using different instruments. To compare the mean values of the measurements, a repeated measures ANOVA was used.</p><p><strong>Results: </strong>Simulated keratometry (Sim-K), central corneal thickness (CCT), keratometric astigmatism magnitude (KAM), and total corneal power (TCP) showed a good agreement (ICC > 95%, ANOVA p > 0.05). Although posterior keratometry (PK) showed no significant differences, its Cronbach's alpha and ICC were low, indicating limited agreement. Corneal diameter showed moderate to poor ICC (p<0.001). Anterior chamber depth (ACD) showed the highest values when assessed with the Anterion; however, the results did not show a statistical significance (p > 0.05).</p><p><strong>Conclusion: </strong>Both Scheimpflug camera devices and AS-OCT were suitable instruments for evaluating the cornea before refractive surgery. A strong correlation was seen for Sim-K, CCT, CD, and TCP; however, notable discrepancies were identified in posterior keratometry, astigmatism magnitude, and ACD. These findings underscore the importance of device-specific factors in assessing corneal and anterior segment measures during refractive surgery evaluations.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"3487-3495"},"PeriodicalIF":0.0,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12457080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145152217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Intravitreal Conbercept in Vitrectomy for Proliferative Diabetic Retinopathy: An Integrated Meta-Analysis and Bibliometric Study.","authors":"Guangda Li, Mingxuan Zhang, Yifeng Ke, Chuanzhen Zheng, Liangzhang Tan, Yongtao Li, Emmanuel Eric Pazo, Chunli Chen, Xinjun Ren","doi":"10.2147/OPTH.S516425","DOIUrl":"10.2147/OPTH.S516425","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the effectiveness of intravitreal Conbercept administered before or during vitrectomy in patients with proliferative diabetic retinopathy (PDR), additionally, a bibliometric analysis was performed.</p><p><strong>Methods: </strong>The literature search was conducted using keywords and terms combined as follows: \"conbercept\", \"vitrectomy\", and \"proliferative diabetic retinopathy\", from January 2012 to August 2024. Additionally, we conducted three different comparisons. Data for the bibliometric analysis were obtained from the Web of Science database and analyzed using VOSviewer and Bibliometrix applications.</p><p><strong>Results: </strong>A total of 16 studies encompassing 1,215 cases were analyzed in this review. Patients in the Conbercept group demonstrated significantly greater improvements in best corrected visual acuity (BCVA) compared to the no injection group at six-month follow-ups (MD = -0.36, 95% CI -0.45 to -0.28, P < 0.01). Additionally, the Conbercept group experienced fewer intraoperative complications, including reduced incidences of intraoperative bleeding (OR = 0.12, 95% CI 0.07 to 0.21), use of endodiathermy (OR = 0.26, 95% CI 0.15 to 0.47), silicone oil tamponade (OR = 0.50, 95% CI 0.35 to 0.73), and iatrogenic breaks (OR = 0.25, 95% CI 0.13 to 0.48). Both early and late postoperative vitreous hemorrhages were less common in the Conbercept group. When administered during vitrectomy, Conbercept still showed superior BCVA improvement at six months (MD = -0.32, 95% CI -0.46 to -0.18, P < 0.01). No significant difference was found between Conbercept and Ranibizumab in BCVA or intraoperative outcomes. From 2015 to 2025, 5,065 publications on Conbercept emerged, with declining growth but strong global collaboration and relevance in anti-VEGF ocular therapy.</p><p><strong>Conclusion: </strong>This systematic review revealed that, similarly to other anti-VEGF injections, Conbercept injection improved BCVA and had lower rates of intraoperative and postoperative complications. Conbercept research shows strong global collaboration and evolving focus on clinical applications in retinal vascular disease management.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"3465-3486"},"PeriodicalIF":0.0,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12461740/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145187753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Visual Outcomes Following Hyperbaric Oxygen Therapy in Acute Central Retinal Artery Occlusion Patients.","authors":"Somanus Thoongsuwan, Thanut Sirichayaporn, Nuttawut Rodanant, Nopasak Phasukkijwatana, Supalert Prakhunhungsit, Nida Wongchaisuwat, Chinnapat Montrisuksirikun, Adisak Trinavarat, Kusuma Chinaroonchai, Supathida Jiamsawad","doi":"10.2147/OPTH.S510772","DOIUrl":"10.2147/OPTH.S510772","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the efficacy of a novel HBOT protocol, characterized by specific pressure levels and treatment duration in patients with CRAO patients presenting within 24 hours, compared to a non-HBOT cohort.</p><p><strong>Patients and methods: </strong>This retrospective cohort study included patients diagnosed with CRAO presenting within 24 hours from October 2003 to March 2022. Patients treated with intravenous recombinant tissue plasminogen activator (rt-PA) or experiencing treatment-related visual complications were excluded. Of 49 eligible patients, 17 underwent HBOT following the novel protocol, while 32 received standard care (non-HBOT).</p><p><strong>Results: </strong>Baseline logMAR VA was 2.3 in both groups. At discharge, 76.5% of the HBOT group exhibited a VA improvement of at least 0.3 logMAR, compared to 40.6% in the non-HBOT group (p = 0.02). Mean logMAR VA at discharge was 1.4 ± 0.8 in the HBOT group and 2.0 ± 0.8 in the non-HBOT group. After one month, the mean logMAR VA remained at 1.4 ± 0.9 in the HBOT group and was 1.9 ± 0.9 in the non-HBOT group.</p><p><strong>Conclusion: </strong>While constrained by the small sample size and short-term outcome data, these results showed the benefits of this unique HBOT protocol in CRAO presenting within the critical 24-hour window. Nevertheless, further prospective validation is necessary before widespread clinical adoption.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"3419-3429"},"PeriodicalIF":0.0,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12452972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145133128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Initial Visual and Refractive Outcomes of Keratorefractive Lenticule Extraction Using 2MHz Femtosecond Laser Platform.","authors":"Anuja Desai, Ravish Kinkhabwala, Parin Mehta, Bhavik Prajapati","doi":"10.2147/OPTH.S548323","DOIUrl":"10.2147/OPTH.S548323","url":null,"abstract":"<p><strong>Purpose: </strong>To report the initial refractive and visual outcomes of keratorefractive lenticule extraction (KLEx) procedures using the 2MHz femtosecond laser platform in myopia and myopic astigmatism.</p><p><strong>Methods: </strong>All eyes meeting the following inclusion and exclusion criteria from April to June 2024 were selected for the study. The study included patients >18 years of age with vision 20/25 or better, myopia with SEQ of -0.5D to -12.5D, residual stromal thickness >300 microns and stable refraction for one year. Excluded were those with hypermetropia, mixed astigmatism, corneas <480 microns, corneal diseases, active illnesses, pregnancy, abnormal corneal shape, and patients not able to commit to a 3-month follow-up.</p><p><strong>Results: </strong>A total of 198 eyes (102 patients) comprising 45 (44.1%) females and 57 (55.9%) males, with a mean age of 23.9 ± 4.8 years, were considered for statistical analysis. 90.4% of the eyes achieved 20/20 UDVA or better after surgery. Correlation between attempted SEQ and achieved SEQ was 0.9636 implying high predictability. Our study demonstrated high accuracy with 100% eyes achieving SEQ ± 1.00D of intended target and 91.9% of eyes within 0.5D of intended target SEQ. The present study confirms the refractive stability with minimal changes (-0.04D relative to the intended target) over 3 months of follow up.</p><p><strong>Conclusion: </strong>The present study shows that the KLEx procedure is highly efficacious and safe, with visual and refractive outcomes showing good predictability and stability.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"3431-3437"},"PeriodicalIF":0.0,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12453037/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145133071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}